Evaluation Of Risk-Benefit Balance
The data produced from clinical trials is usually more thorough than that received through typical channels of spontaneous reporting. Similarly, the steps for follow-up are often far easier to take. Nevertheless, you will need to demonstrate consistently that your reporting process is adequately specified and resourced to the task.
Expedited reporting requirements mean your standard operating protocol (SOPs) must include the accurate grading of incidents within an acceptable timescale. Our team at Almond Pharma have the experience to advise on the grading process to account for the delivery of timely and accurate compliance. Their input is also critical when it comes to demonstrating your analysis of risk-benefit ratios.
During any pre-marketing trial, your company requires your investigator to specify which events are considered serious and unexpected within your reporting. Your investigator must also make you aware of particular types of non-serious adverse events or laboratory findings. Serious Adverse events (SAEs) must be reported to the regulatory authorities within specified timelines. If the adverse reactions are classified as fatal or life-threatening they should be reported within 7 days, as non-fatal, non-life-threatening SUSARS are reported within 15 days.
Almond Pharma’s experienced consultants interpret the case reports within the necessary Pharmacovigilance legal framework. Your submissions to the regulators will always be on time and you will not need to worry about penalties stemming from non-compliance.
© 2020 ASAAL ltd
Registered in the UK, Company number 06830591